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a  b  s  t r  a  c  t
We conducted  a  population  telephone  survey  in Hong  Kong  during  the  second  wave  of inﬂuenza  A/H7N9
outbreak  in  2014.  Among  the  respondents,  50.5%  of  the respondents  would  like  to  accept  A/H7N9  vac-
cination  in future.  Respondents  had  poor  knowledge  of  A/H7N9  inﬂuenza  and  vaccines.  More  than  60%
of  respondents  mixed  up seasonal  inﬂuenza  this  year  and  A/H7N9  inﬂuenza.  Results  show  that  socio-





vaccine  history  were  the  main  affecting  factors.  Vaccine  promotion  strategies  may  focus  on  inﬂuenza
knowledge,  attitude  and  behavior.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).ong Kong
. Introduction
Human infected A/H7N9 inﬂuenza virus case was  ﬁrst identi-
ed in Eastern China in March 2013 and re-emerged in December
013. Current evidence of sustained human-to-human transmis-
ion is rare, but small cluster of infected cases within a few family
ave been observed. There are continuous threads that A/H7N9
ill become another pandemic virus due to viral re-assortment
1]. Vigilant protective measures against spreading of disease were
xecuted, both internationally and locally [2].
Vaccines remain one of the most effective strategies in control-
ing epidemics. Acceptability of a novel inﬂuenza vaccine depends
n interactions of product, viral, individual and social factors [3,4].
urrently (as of August 2015) the efﬁcacy of human A/H7N9 vac-
ines had not been proven. The World Health Organization had
ecommended candidate viruses for vaccine manufacture. Vaccine
evelopment is still in progress [5].
Inﬂuenza transmission in Hong Kong can be rapid and become
ncontrollable due to high population density. Sources of outbreak
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unwere also difﬁcult to avoid due to frequent mixing of people in
Hong Kong and mainland China. Understand the willingness of
A/H7N9 inﬂuenza vaccine taking in the community help policy
makers to decide suitable strategies to control the re-emerging of
this inﬂuenza virus.
2. Methods
We conducted a cross-sectional, population-based telephone
survey between 15 and 28 February 2014 in Hong Kong. Substan-
tial conﬁrmed A/H7N9 human cases were found in China and the
seasonal inﬂuenza activity was  high in Hong Kong at that time [6].
We excluded population aged below 15 years. Randomly generated
telephone numbers from the list of all land-based telephone num-
bers in Hong Kong was used to provide the study sample. Calls were
made in the evening on weekdays and whole day on weekends to
prevent over representation of the unemployed population. Sub-
jects undergoing the interview was  chosen by whose last birthday
was closest to the interview date [7]. The numbers were called for
a maximum of 5 times before being classiﬁed as unanswered.
The study instrument consisted of close ended questions that
aimed to collect socio-demographic information, knowledge atti-
tudes and practices (KAP) of preventive measures against human
A/H7N9 inﬂuenza infections. Questions were modiﬁed from pre-
vious related inﬂuenza studies [8,9]. The survey questionnaire
was pilot tested in January 2014 (n = 50) to ensure practicability,
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table  1
Socio-demographic characteristics of the respondents and the general population in Hong Kong in 2011.
Demographics Sample population Hong Kong population 2011 Sample vs. census P-valuea
n % %
Age (n = 1020)
15–24 143 14.0 14.0 0.99
25–44  348 34.1 35.5
45–64  363 35.6 35.4
≥65  166 16.3 15.1
Gender (n = 1020)
Male 461 45.2 46.0 1.00
Female 559 54.8 54.0
Education (n = 1019)
Primary education or below 138 13.5 22.7 0.18
Secondary education 517 50.7 50.0
Post-secondary education (including diploma and certiﬁcate) 364 35.7 27.3
Occupation (n = 1006)
White collar 411 40.9 NA
Blue collar 96 9.5 NA
Housewife, retired or unemployed 393 39.1 NA
Students 106 10.5 NA
Area  of Residence (n = 1020)
Hong Kong Island (wealthy district) 185 18.1 18.0 1.00
Kowloon (densely populated district) 308 30.2 29.8
New Territories (suburb district) 527 51.7 52.2
Marital status (n = 1018)
Single 355 34.9 42.2 0.36
Married 663 65.1 57.8
Household income (n = 969)
<$10,000 135 13.9 23.8 0.30
$10,000–19,999 220 22.7 23.8
$20,000–39,999 346 35.7 29.0
≥$40,000 268 27.7 23.5
Type  of housing (n = 1017)
Public housing 387 38.1 30.3 0.61b
Subsidized home ownership housing 160 15.7 15.9
Private permanent housing 455 44.7 52.3




















aChi-square test was used to measure the overall difference in proportions betw
igniﬁcant difference.
b Fisher-exact test P-value was used.
alidity, and interpretation of answers. This study was approved
y the Survey and Behavioral Research Ethics Committee of The
hinese University of Hong Kong.
Differences in proportions between demographic characteris-
ics in this survey and the Hong Kong Population Census data in
011 were examined. Descriptive statistics for knowledge, attitude
nd practice of H7N9 inﬂuenza A prevention in the study popula-
ion were calculated. We  conducted univariate analyses to identify
pparent associations between socio-demographic, knowledge,
ttitude factors and the willingness to take future A/H7N9 inﬂuenza
accine. A stepwise multivariable logistic regression was  then con-
ucted using variables with at least marginal statistical association
n the univariate analysis (p < 0.10). All statistical analyses were
onducted using R (version 3.0.2, R Development Core Team 2011).
tatistical signiﬁcance was set at  ˛ = 0.05 two-sided.
. ResultsFinal response rate was  72.0% (1020/1416). Socio-demographic
haracteristics of the study population were comparable to the gen-
ral population in Hong Kong in 2011 [10] in terms of age, sex and
rea of residence (Table 1).is survey and the 2011 Hong Kong Population Census data. P-value < 0.05 indicates
The mean state-trait anxiety inventory score was 1.84/4
(Standard Deviation 0.62), indicating low risk perception among
the respondents toward inﬂuenza infections. 62.5% of the respon-
dents misinterpreted A/H7N9 inﬂuenza is the seasonal inﬂuenza
of 2013–2014. For knowledge about inﬂuenza vaccines, 36.3% had
the misconception of seasonal inﬂuenza vaccine can protect human
from A/H7N9 infections. Only 61.3% correctly stated the seasonal
vaccine protection can last for one year but not a longer time period.
Around one tenth (11.1%) did not know how long will the protection
last for.
For vaccine history, only 14.3% of respondents regularly took
seasonal inﬂuenza vaccination. 14.4% had taken seasonal ﬂu shot
in the past 6 months and 21.5% said they will probably take seasonal
ﬂu shots in future. Half (50.1%) of the respondents expressed their
interest on A/H7N9 inﬂuenza vaccine uptake in future. The main
reason for taking was  to protect themselves from infections (95.0%).
For those who  showed no interest to take A/H7N9 vaccine, the main
reason was  they thought it is unnecessary (70.0%), followed by they
thought the vaccine is not useful as it will still get infected after
vaccination (15.0%). We  categorized the respondents into groups
deﬁned by the stages of change theory using their vaccine history
[11] (Table 2). We  found the pre-contemplation group, which did
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Table  2
Stages of change categorized by seasonal inﬂuenza vaccine history.
Seasonal inﬂuenza vaccine history
Stages of changea Past record This year (2013–2014) Future Frequency %
Pre-contemplation Never NA Unlikely 411 40.3
Contemplation Never NA Half/half 205 20.1
Preparation Never NA Likely 43 4.8
Action Sometimes Yes Half/half or likely 14 1.5
Maintenance Regular Yes Half/half or likely 104 12.1
Relapse Sometimes or regular No Unlikely 122 19.4
Undeﬁned 11 1.9
Total  1020 100.0
a Prochaska JO, Velicer WF.  The transtheoretical model of health behavior change. Am J Health Promot 21(2); 1997: 38–48.
Table 3
Multivariable logistic regression analysis of the key knowledge, attitude and practice predictors for attitude toward willingness of inﬂuenza A/H7N9 vaccine uptake.
Willingness to take H7N9 inﬂuenza vaccine in future
Unadjusted Adjusted
Characteristics OR (95% CI) P-value OR (95% CI) P-value
Believed A/H7N9 is seasonal inﬂuenza subtype in 2013–2014
Not agree 1 1
Agree  2.03 (1.54–2.68) <0.01 1.66 (1.23–2.23) <0.01
Thought seasonal ﬂu vaccination can protect from A/H7N9 infections
No 1 1
Yes  2.10 (1.62–2.72) <0.01 1.69 (1.28–2.25) <0.01
Have  the habit of regular seasonal inﬂuenza vaccines uptake
No  1 1
Yes  7.33 (4.43–12.11) <0.01 2.78 (1.29–6.01) 0.01
Have  received seasonal ﬂu vaccines in the past 6 months (2013–2014 strains)
No 1 1
Yes  6.77 (4.18–10.97) <0.01 2.78 (1.30–5.79) 0.01
State-Trait Anxiety Inventory score (range 1–4)























sectional telephone survey. For our sample population, they hadLow  (1.50–1.99) 
Medium (2.00–2.49)
High  (>2.49) 
ot have any inﬂuenza vaccine uptake in previous and not likely
o take inﬂuenza vaccine in future, showed much lower preference
or the decision of taking future A/H7N9 inﬂuenza vaccines when
ompared to other groups.
A stepwise multivariable logistic regression revealed that socio-
emographic factors including age, sex, education, occupation,
eligion, having chronic illnesses, household income, type of hous-
ng and area of residence were all independent of the willingness.
nterestingly, those with misconception that A/H7N9 is the sea-
onal inﬂuenza of the current year and those who believed
easonal inﬂuenza vaccines can protect A/H7N9 infections showed
ncreasing interest in future A/H7N9 vaccine uptake. Meanwhile
aving seasonal inﬂuenza vaccination history and higher anx-
ety score was correlated with the uptake willingness (Table
).
. Discussion
We  found more than 60% of people in Hong Kong commu-
ity had misconceptions about inﬂuenza and its vaccines. We also
ound the willingness of taking A/H7N9 vaccine was independent of
emographic factors. This founding contrasted with previous stud-
es that male sex, younger age and higher education are more likely
o receive pandemic inﬂuenza vaccines [12]. Interestingly we  found
hose respondents who mixed up seasonal and A/H7N9 inﬂuenza
ere more willing to take A/H7N9 vaccine. Those people might1.66 (1.18–2.33) <0.01 1.62 (1.13–2.33) 0.01
2.46 (1.74–3.48) <0.01 2.39 (1.65–3.46) <0.01
3.63 (2.43–5.43) <0.01 3.15 (2.06–4.84) <0.01
learn from previous experience that A/H1N1 pandemic inﬂuenza
virus had become one of the circulating viruses in the subsequent
seasons after 2009.
Based on the results, population based vaccine promotion
strategies that focus on inﬂuenza knowledge and attitude maybe
more suitable in Hong Kong.
The characteristics of other low pathogenic and/or low trans-
missibility inﬂuenza sub-types hindered future A/H7N9 vaccine
promotions. Unlike the detrimental experience of SARS in 2003, the
experience of inﬂuenza in Hong Kong (A/H5N1 outbreak in 1997
and A/H1N1 pandemic in 2009) did not result huge impact in the
society [13]. This was reﬂected by the low anxiety level even though
the survey was  done after re-emergence of A/H7N9 and in a high
seasonal ﬂu season. Perception of vaccine failure was found com-
mon  in the respondents. This may  be due to inﬂuenza diagnosis is
essentially base on clinical symptoms. Even the inﬂuenza vaccine
has high efﬁcacy, other type of respiratory infections will still occur
after having ﬂu shot. Whereas the results clearly showed a positive
linear relationship between willingness of vaccine uptake and anx-
iety level, strategies to increase vaccination rates may  focus on this
direction.
Limitations included the methodological limitation of cross-higher household income and education level that the Hong Kong
general population. Nevertheless our results showed these socio-
























[14] Valkenburg SA, Li OTW, Mak PWY, Mok  CKP, Nicholls JM,  Guan Y, et al. IL-
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. Conclusions
Given the pandemic potential of A/H7N9, targeted vaccine is
orth to develop and disseminate to the public. While there are still
ifﬁculties in convincing people about the usefulness of inﬂuenza
accine to treat respiratory infections, perhaps a universal
nﬂuenza vaccine maybe one better solution [14] in future. Nev-
rtheless, concurrent antivirals and non-pharmaceutical strategies
ust run in parallel to reduce the adverse impacts when con-
ronting potential epidemics and pandemics like the A/H7N9
nﬂuenza.
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